-- Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean BMI reduction at 16 weeks -- -- Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity ongoing; completion of enrollment expected 1Q 2024 -- BOSTON, June 17, 2023...

BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway ...

- Interview-based research published in Advances in Therapy demonstrates setmelanotide improved hyperphagia and reduced body weight and obsessive focus on food - Company also announces publication of health state utilities study in hyperphagia - BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Rhythm ...

- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit with Rhythms rare endocrinology focus and provides meaningful new development opportunity - - Expect to initiate clinical development in 2024 - BOSTON and AMSTERDAM, Feb. 27, 2023...